Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 5, 2009, Pages

  Umar, Soban ^a   De Visser, Yvonne P ^a   Steendijk, Paul ^a   Schutte, Cindy I ^a   Laghmani, El Houari ^a   Wagenaar, Gerry T M ^a   Bax, Wilhelmina H ^a   Mantikou, Eleni ^a   Pijnappels, Daniel A ^a   Atsma, Douwe E ^a   Schalij, Martin J ^a   Van Der Wall, Ernst E ^a   Van Der Laarse, Arnoud ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Heart failure; Hypertrophy; Monocrotaline; Pulmonary arterial hypertension; Remodeling

Indexed keywords

MONOCROTALINE; VASCULOTROPIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE FUNCTION; ISOLATION PROCEDURE; LUNG ARTERY PRESSURE; LUNG WEIGHT; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PULMONARY HYPERTENSION; RAT;

ANIMALS; ARTERIOLES; CARDIAC OUTPUT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEART RATE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION MEDIATORS; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MONOCROTALINE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PULMONARY ALVEOLI; PULMONARY ARTERY; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; RNA, MESSENGER; STROKE VOLUME; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 70350439907     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00590.2009     Document Type: Article

References (52)

1. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation 102: 2781-2791, 2000.
2. Baber SR, Deng Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL, Kadowitz PJ. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 292: H1120-H1128, 2007. (Pubitemid 46246966)
3. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289: H501-H512, 2005. (Pubitemid 41129360)
4. Campbell AIM, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104: 2242-2248, 2001. (Pubitemid 33043307)
5. Crisostomo PR, Markel TA, Wang M, Lahm T, Lillemoe KD, Meldrum DR. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 142: 215-221, 2007. (Pubitemid 47198676)
6. Dantzker DR, Bower JS. Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. J Clin Invest 64: 1050-1055, 1979.
7. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 22: 358-363, 2003.
8. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351: 1655-1665, 2004.
9. Flamme I, Breier G, Risau W. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev Biol 169: 699-712, 1995.
10. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, d'Ortho MP. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 18: 838-845, 2001. (Pubitemid 33076927)
11. Fujita M, Mason RJ, Cool C, Shannon JM, Hara N, Fagan KA. Pulmonary hypertension in TNF-α-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 93: 2162-2170, 2002. (Pubitemid 35379344)
12. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol Heart Circ Physiol 240: H149-H155, 1981. (Pubitemid 11155908)
13. Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T. Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in SD constructs. J Cell Physiol 207: 331-339, 2006.
14. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 358: 948-953, 2007. (Pubitemid 46802482)
15. Hessel MHM, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 291: H2424-H2430, 2006. (Pubitemid 44776673)
16. Hincks JR, Kim HY, Segall HJ, Molyneux RJ, Stermitz FR, Coulombe RA Jr. DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity relationships. Toxicol Appl Pharmacol 111: 90-98, 1991.
17. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135: 799-808, 2008.
18. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79: 1131-1142, 1996. (Pubitemid 26404145)
19. Jones PL, Cowan K, Rabinovitch M. Tenascin-C, proliferation and subendothelial accumulation of fibronectin in progressive pulmonary vascular disease. Am J Pathol 150: 1349-1360, 1997. (Pubitemid 27152653)
20. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106: 589-597, 2000. (Pubitemid 30666392)
21. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, Katsumata T. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114, Suppl I: I-181-I-185, 2006. (Pubitemid 44297148)
22. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 13: 419-425, 2006.
23. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume M, Mukaida N, Matsushima K, Kuriyama T. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 78: 571-581, 1998. (Pubitemid 28246981)
24. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109: 1543-1549, 2004. (Pubitemid 38420184)
25. Lalich JJ, Merkow L. Pulmonary arteritis produced in rats by feeding Crotolaria spectabilis. Lab Invest 10: 744-750, 1961.
26. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun- Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63, 2009.
27. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol 187: 345-355, 2001.
28. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989. (Pubitemid 20066716)
29. Lopes AA, Maeda NY, Gonçalves RC, Bydlowski SP. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 139: 618-623, 2000.
30. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med 327: 117-119, 1992.
31. Mattocks AR, Jukes R, Brown J. Simple procedures for preparing putative toxic metabolites of pyrrolizidine alkaloids. Toxicon 27: 561-567, 1989. (Pubitemid 19121751)
32. Melot C, Naeije R, Mols P, Vandenbossche JL, Denolin H. Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. Chest 83: 203-207, 1983. (Pubitemid 13185688)
33. Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol Heart Circ Physiol 239: H692-H702, 1980. (Pubitemid 11241499)
34. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara T, Hara H, Mori H. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108: 889-895, 2003. (Pubitemid 37022134)
35. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O- (2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163: 498-502, 2001. (Pubitemid 32158536)
36. Olsson MC, Palmer BM, Leinwand LA, Moore RL. Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 280: H1136-H1144, 2001. (Pubitemid 32537875)
37. Passier R, Mummery C. Origin and use of embryonic and adult stem cells in differentiation and tissue repair. Cardiovasc Res 58: 324-335, 2003. (Pubitemid 36570391)
38. Patel KM, Crisostomo P, Lahm T, Markel T, Herring C, Wang M, Meldrum KK, Lillemoe KD, Meldrum DR. Mesenchymal stem cells attenuate hypoxic pulmonary vasoconstriction by a paracrine mechanism. J Surg Res 143: 281-285, 2007. (Pubitemid 350101559)
39. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
40. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999. (Pubitemid 29282067)
41. Potier E, Ferreira E, Andriamanalijaona R, Pujol JP, Oudina K, Logeart-Avramoglou D, Petite H. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 40: 1078-1087, 2007. (Pubitemid 46386551)
42. Raoul W, Wagner-Ballon O, Saber G, Hulin A, Marcos E, Giraudier S, Vainchenker W, Adnot S, Addahibi S, Maitre B. Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice. Resp Res 8: 8, 2007.
43. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26: 2173-2182, 2008.
44. Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, Nagai R. Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation 115: 509-517, 2007. (Pubitemid 46184202)
45. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45, 2004. (Pubitemid 38233887)
46. Sehgal PB, Mukhopadhyay S, Xu F, Patel K, Shah M. Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292: L1526-L1542, 2007. (Pubitemid 47077370)
47. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, Rockman HA, Korach KS, Murphy E. Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 288: H469-H476, 2005. (Pubitemid 40139627)
48. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng 10: 771-779, 2004. (Pubitemid 38880395)
49. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11: 664-675, 1994.
50. Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 22: 307-325, 1992. (Pubitemid 23014739)
51. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells. Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96: 442-450, 2005. (Pubitemid 40354538)
52. Zhao YD, Courtman DW, Ng DS, Robb MJ, Deng YP, Trogadis J, Han RNN, Stewart DJ. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 35: 182-189, 2006. (Pubitemid 44175317)